Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei.

Trial Profile

Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Fibrinogen (Primary) ; Fibrinogen
  • Indications Surgical blood loss
  • Focus Therapeutic Use
  • Acronyms FORMA-05
  • Sponsors Octapharma
  • Most Recent Events

    • 04 Dec 2018 Interim results (n=23) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 17 Oct 2018 Interim results (n=23) presented at the ANESTHESIOLOGY 2018: Annual Meeting of the American Society of Anesthesiologists
    • 06 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top